Single chemotherapy instillation after ureteroscopy for UTUC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of a single chemotherapy bladder instillation following endoscopic treatment for upper tract urothelial carcinoma (UTUC). Participants will receive the chemotherapy within 24 hours after undergoing ureteroscopy, and their outcomes will be monitored through routine follow-up, including cystoscopy. The primary goal is to determine if this intervention can reduce the incidence of intravesical recurrence (IVR) in patients suspected of having UTUC. The study aims to build on existing evidence suggesting that post-operative chemotherapy can lower IVR rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Radiographic and/or cytological suspicion for UTUC
* Planned endoscopic procedure for treatment / diagnosis of UTUC
* Patients with bladder cancer history are eligible if meeting both following criteria:

No recurrence within the last two years Are not on active bladder irrigation protocol

* Patients with history of UTUC are eligible if last endoscopic treatment or RNU was \>1 year prior to enrollment
* Age ≥ 18 years
* Performance status ECOG 0-2

Exclusion Criteria:

* Subjects who have had bladder / prostate radiotherapy
* Subjects with bladder cancer history on active bladder irrigation protocols or with active disease within two years prior to enrollment
* Subjects with previously treated UTUC within one year prior to enrollment
* Subjects with metastatic disease

Where it's running

• Assuta Ashdod Hospital
  Ashdod, Israel Recruiting
• Soroka University Medical Center
  Beersheba, Israel Recruiting
• Shamir Medical Center
  Be’er Ya‘aqov, Israel Recruiting
• Bnai Zion Medical Center
  Haifa, Israel Recruiting
• Carmel Medical Center
  Haifa, Israel Recruiting
• Rambam Health Care Campus
  Haifa, Israel Recruiting

Study contacts

• Study coordinator: Yuval Freifeld, Dr
• Email: yuvalfr@clalit.org.il
• Phone: +972-4-8250843

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Urine test to detect urological cancers in people with blood in urine

  This study tests whether a urine fluorescence test can help find urological cancers in adults with hematuria before biopsy.

  Recruiting Ruijin Hospital · Shanghai · NCT07813260

• Trastuzumab Rezetecan and Gemcitabine before surgery for HER2-positive UTUC

  This study tests whether giving trastuzumab deruxtecan with gemcitabine before and around surgery can improve outcomes for people with HER2-positive upper tract urothelial cancer.

  Recruiting at 10 sites Phase 2 Tongji Hospital · Huanggang, Hubei and 9 other locations · NCT07741448

• Non-invasive urine test to screen for urothelial cancer in adults with blood in urine

  A noninvasive urine test is being used to see if it can correctly identify urothelial cancer in adults who have blood in urine and a suspicious imaging finding.

  Recruiting Henan Provincial People's Hospital · Zhengzhou, Henan · NCT07614594

• Monitoring recurrence of urothelial carcinoma using urinary tests

  This study is testing if urine tests can help track the return of urothelial carcinoma in patients with different types of bladder and kidney cancer.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT06991868

• Combination treatment for HER2-positive upper tract urothelial carcinoma after surgery

  This study is testing a new combination of targeted therapy and immune treatment to see if it helps prevent cancer from coming back in patients with HER2-positive upper tract urothelial carcinoma after surgery.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT05917158

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.